CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

NCT04480788 | Unknown Phase 1

• 1 other identifier: PG-CART-07-001
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

Phase I was a single arm, open label, dose increasing study to explore the safety, tolerance and Cytodynamic characteristics of the drug, and to preliminarily observe the efficacy of the study drug in relapsed / refractory CD7 Positive hematolymph system malignant tumor patients, so as to explore the clinical applicable dose of phase II. Since the activity and toxicity of cellular drugs (long-term survival drugs) do not have obvious dose dependence, and the increase of their dose may be accompanied by the increase of toxicity, rather than necessary for therapeutic effect, it is not necessarily suitable to recommend the effective dose according to the maximum tolerable dose (MTD). Therefore, this study will be based on the safety data, as well as the preliminary efficacy, efficacy and drug The end point of pharmacokinetics (ORR, the content of CD7 Positive Cells, the expansion and duration of car-t cells) were comprehensively considered to determine the recommended dose for phase II clinical trial.Main research purposes Objective to evaluate the safety and tolerability of T cell injection targeting CD7 autologous chimeric antigen receptor in the treatment of relapsed / refractory CD7 Positive hematological and lymphoid malignancies.

Conditions

T Lymphoblastic Leukemia/Lymphoma; Extramedullary NK-T-cell Lymphoma, Nasal Type; Peripheral T-cell Lymphoma, Nonspecific; Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma; Anaplastic Large Cell Lymphoma, ALK-negative; T-cell Lymphoblastic Leukemia

Outcome Measures

Primary Outcomes (1)

• Dose-limiting toxicity (DLT)

  Up to 2 years

Secondary Outcomes (11)

• Safety results

  Up to 2 years

• PK

  Up to 2 years

• PK

  Up to 2 years

• PK

  Up to 2 years

• PD

  Up to 2 years

Study Arms (1)

T cell injection targeting CD7 chimeric antigen receptor

EXPERIMENTAL

Biological: T cell injection targeting CD7 chimeric antigen receptor

Interventions

T cell injection targeting CD7 chimeric antigen receptor BIOLOGICAL

Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation

T cell injection targeting CD7 chimeric antigen receptor

Eligibility Criteria

• Age: 7 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• The age ranged from 7 to 70 years (including the cut-off value), regardless of gender
• The expected survival time was more than 6 weeks
• ECOG score 0-1
• Malignant lymphoma (including but not limited to acute T-lymphoblastic leukemia / lymphoma; extramedullary NK / T-cell lymphoma, nasal type; peripheral T-cell lymphoma, nonspecific; vascular immunoblastic T-cell lymphoma; intestinal disease associated T-cell lymphomas; anaplastic large cell lymphoma (ALK -); T-cell lymphoblastic leukemia)
• When screening, hematological malignancies with CD7 Positive confirmed by bone marrow examination or tumor pathology with positive rate of CD7 ≥ 30%, meeting one of the following conditions:
• At least two chemotherapy regimens failed or did not achieve complete remission or relapse;
• Patients who relapsed after stem cell transplantation were not affected by other treatment methods;
• For peripheral blood involved acute T-lymphoblastic leukemia / lymphoma and NK / T-cell lymphoma, patients with TCR rearrangement were detected by ngs
• The liver and kidney function, heart and lung function meet the following requirements:
• Creatinine ≤ 1.5 ULN;
• LVEF ≥ 45%;
• Blood oxygen saturation \> 91%;
• The total bilirubin ≤ 2 × ULN; ALT and AST ≤ 2.5 × ULN; the abnormal ALT and AST caused by diseases (such as liver infiltration or bile duct obstruction) can be relaxed to ≤ 5 × ULN;
• Understand the experiment and have signed the informed consent

You may not qualify if:

• Those who need immunosuppressant;
• For intestinal disease-related T-cell lymphoma, patients with intestinal ulcer or hematochezia were examined by colonoscopy;
• In addition to cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical operation, and breast ductal carcinoma in situ after radical operation;
• The patients with positive HBsAg or HBcAb and HBV DNA titer in peripheral blood were not within the normal reference value; those with positive anti HCV antibody and positive HCV RNA in peripheral blood; those with HIV antibody positive and cytomegalovirus DNA positive Syphilis was positive;
• Severe heart disease: including but not limited to unstable angina pectoris, myocardial infarction (within 6 months before screening), congestive heart failure (NYHA classification ≥ III), severe arrhythmia;
• Unstable systemic diseases judged by researchers: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;
• Within 7 days before screening, there were active or uncontrollable infections requiring systemic treatment (except for mild genitourinary system infection and upper respiratory tract infection);
• Pregnant or lactating women, female subjects planning pregnancy within 1 year after cell reinfusion or male subjects whose partners plan to conceive within 1 year after cell reinfusion;
• Patients who had received car-t therapy or other gene modified cell therapy before screening;
• Subjects who were receiving systemic steroid therapy or were receiving systemic steroid therapy for 7 days were excluded;
• Participated in other clinical studies within 3 months before screening;
• There was evidence of central nervous system invasion during screening;
• According to the judgment of the researchers, it does not conform to the condition of cell preparation;
• Other researchers think it is not suitable to be included in the study.

Sponsors & Collaborators

• PersonGen BioTherapeutics (Suzhou) Co., Ltd.: lead
• The First Affiliated Hospital of Zhengzhou University: collaborator

Study Sites (1)

First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450000, China

RECRUITING

MeSH Terms

Conditions

Lymphoma; Lymphoma, T-Cell, Peripheral; Immunoblastic Lymphadenopathy; Enteropathy-Associated T-Cell Lymphoma; Lymphoma, Large-Cell, Anaplastic

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphadenopathy

Central Study Contacts

Mingzhi Zhang, Doctor

CONTACT

+8613838565629; mingzhi_zhang@126.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: CD7-CART

Study Record Dates

• First Submitted: July 14, 2020
• First Posted: July 21, 2020
• Study Start: November 24, 2020
• Primary Completion: August 1, 2022
• Study Completion: August 31, 2022
• Last Updated: January 6, 2021

Record last verified: 2021-01

Locations

CN (1)